Sanofi settles dispute with Genzyme investors over MS drug

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payme

Regeneron/Sanofi get EU okay for Dupixent in “asthma of the ...

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

Sanofi opens digital biologics manufacturing site

Sanofi has opened a manufacturing facility in the US, one of the world’s first facilities using digital continuous biologics production technology.

Sanofi’s Dupixent backed for nasal polyps use in Europe